Seqens takeover confirmed

SK Capital Partners has announced that it, Eurazeo and other shareholders in Seqens have entered a formal agreement for it to acquire Seqens. This follows a period of exclusive negotiations and the agreement of the employee representative body. This remains subject to regulatory approval. S

K Capital said that this deal “represents a key investment in an integrated global leader active in pharmaceutical solutions and specialty ingredients, through various complementary business units”. It plans to merge US-based Wavelength Pharmaceuticals with Seqens “to create a global leader in the API and CDMO sectors”.

Separately, Seqens has opened its new 1200 m2 cGMP pharmaceutical QC laboratory at its salicylic acid production site in Roussillon, France, with Prime Minister Jean Castex. This was built with the 2003 opening of a €100 million, 10,000 tonnes/year paracetamol production unit in mind. The facility also includes a control room and administrative office area.